Purple Biotech (PPBT) Cash & Current Investments (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Cash & Current Investments data on file, last reported at $6.4 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 2.9% year-over-year to $6.4 million in Q1 2026; TTM through Mar 2026 was $6.4 million, a 2.9% decrease from a year earlier, with the FY2025 full-year figure at $9.6 million, up 752.54% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $6.4 million, down from $9.6 million in the prior quarter.
• Over the last five years, Cash & Current Investments for PPBT reached as high as $39.5 million in Q1 2022 and fell as low as $1.1 million in Q4 2024.
• Historically, Cash & Current Investments has averaged $15.3 million across 5 years, with a median of $10.8 million in 2024.
• Across the five-year window, Cash & Current Investments plunged 92.68% in 2024 and jumped 752.54% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $15.5 million in 2022, then fell by 0.79% to $15.3 million in 2023, then plunged by 92.68% to $1.1 million in 2024, then surged by 752.54% to $9.6 million in 2025, then plunged by 32.88% to $6.4 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $6.4 million in Q1 2026, $9.6 million in Q4 2025, and $10.5 million in Q3 2025.